Share:
London, Jan. 14, 2021 (GLOBE NEWSWIRE) -- In its latest publication, titled
"Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin], Application (Immunology, Hematology, Neurology), and End User (Hospital, Clinical Research Lab, Academic Institutes) - Forecast to 2027", Meticulous Research® states that the plasma fractionation market is expected to grow at a CAGR of 7% from 2020 to 2027 to reach $41.4 billion by 2027.
Plasma fractionation is a method of separating various components of blood plasma into its different components. Plasma-derived products are used in the prevention and treatment of life-threatening diseases caused by trauma, immunologic disorders, and infections.
The rising use of immunoglobulins in therapeutic areas, increasing number of chronic diseases, growing prevalence of blood and respiratory disorders, and rising number of plasma collection centers are some of the major factors driving the global plasma fractionation market.